---
schema_version: "secwatch.filing_event.v1"
accession: "0001689375-24-000045"
form_type: "8-K"
ticker: "TRDA"
cik: "0001689375"
company_name: "Entrada Therapeutics, Inc."
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:44:50.557133+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Entrada Q2 net income $55M, positive Phase 1 data for DMD candidate ENTR-601-44

## Summary
- Q2 net income of $55.0M vs net loss of $25.9M YoY; collaboration revenue $94.7M (up from $18.2M).
- Completed $100M registered direct offering; cash & securities $469.7M as of June 30, 2024; runway into 2027.
- Phase 1 trial of ENTR-601-44 showed dose-dependent plasma/muscle concentration and exon skipping; no serious adverse events.
- Planning global Phase 2 trials for ENTR-601-44 and ENTR-601-45; regulatory filings expected Q4 2024; ENTR-601-50 filing planned 2025.
- Vertex VX-670 DM1 trial enrolling; SAD portion expected to complete by end of 2024.

## SEC filing metadata
- accession: 0001689375-24-000045
- form_type: 8-K
- ticker: TRDA
- cik: 0001689375
- company_name: Entrada Therapeutics, Inc.
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689375/000168937524000045/0001689375-24-000045-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689375/000168937524000045/trda-20240813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001689375-24-000045
- JSON: https://secwatch.observer/filing/0001689375-24-000045.json
- Plain text: https://secwatch.observer/filing/0001689375-24-000045.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.